Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Genmab A/S

Genmab ( ($GMAB) ) has provided an update. On November 20, 2025, Genmab A/S announced the grant of 6,933 restricted stock units and 7,377 warrants ...

Genmab Grants Stock Units and Warrants to Employees

Genmab ( ($GMAB) ) just unveiled an update. On November 19, 2025, Genmab A/S announced transactions involving shares and linked securities conducte...

Genmab A/S Discloses Managerial Share Transactions

Genmab ( ($GMAB) ) has provided an announcement. Genmab A/S has updated its Articles of Association, authorizing the Board of Directors to increase...

Genmab A/S Updates Articles of Association to Enhance Capital Flexibility

The latest announcement is out from Genmab ( ($GMAB) ). On November 18, 2025, Genmab A/S announced a capital increase of 32,059 shares following th...

Genmab Announces Capital Increase Following Employee Warrant Exercise

Genmab ( ($GMAB) ) just unveiled an update. On November 18, 2025, Genmab A/S announced that the U.S. FDA approved EPKINLY® (epcoritamab-bysp) in co...

Genmab’s EPKINLY® Combination Therapy Gains FDA Approval for Follicular Lymphoma

In a report released on November 14, Jon Berggren from Kepler Capital maintained a Hold rating on Genmab A/S, with a price target of DKK2,100.00. T...

Genmab A/S (0MGB) Receives a Hold from Kepler Capital

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them this month. These decisio...

REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?

UBS analyst Xian Deng maintained a Buy rating on Genmab A/S on November 7 and set a price target of DKK2,700.00. The company’s shares closed yester...

UBS Remains a Buy on Genmab A/S (0MGB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Genmab (GMAB – Research Report), Aziyo Biologics (ELUT – Research...

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Aziyo Biologics (ELUT) and Ironwood Pharma (IRWD)

Genmab ( ($GMAB) ) has issued an announcement. On November 6, 2025, Genmab announced its financial results for the first nine months of 2025, repor...

Genmab Reports Strong Financial Growth and Announces Acquisition of Merus

Genmab (Otc) (($GMAB)), Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. Genmab and BioNTech SE are collabo...

Current Quarter	$0.45	Next Quarter	$0.28
Current Year	$1.89	Next Year	$1.66
QoQ Growth	-37.8%	YoY Growth	-12.2%
3Y EPS CAGR	+0.0%	Target Price	$37.39
Consensus	Buy	Upside	+22.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GMAB	$30.45	+1.36%	1.04M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GMAB	$30.45	+1.4%	1.04M
3
4
5
6

GMAB

GMAB

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Genmab A/S Data in Excel

Get Genmab A/S Data in Excel